Personalis (PSNL) just wrapped up FY 2025 with Q4 revenue of US$17.3 million and a basic EPS loss of US$0.26, alongside a full year trailing revenue base of US$69.6 million and a trailing EPS loss of US$0.91. Over the last six reported quarters, revenue has moved between US$14.5 million and US$25.7 million per quarter, while quarterly basic EPS has ranged from a loss of US$0.18 to a loss of US$0.64. This underscores a business that is still working through sizeable net losses even as the top line holds in the tens of millions. For investors, the latest print keeps the focus firmly on how quickly margins can tighten up and whether revenue growth can eventually carry the company closer to breakeven.

See our full analysis for Personalis.

With the headline numbers on the table, the next step is to set these results against the widely followed narratives around Personalis's growth potential and ongoing losses to see which stories hold up and which start to look stretched.

Losses Stay Heavy At US$81.3 Million LTM

• On a trailing twelve month basis to Q4 FY 2025, Personalis recorded total revenue of US$69.6 million against a net loss of US$81.3 million, with trailing basic EPS at a loss of US$0.91.
• Bears focus on the size and persistence of these losses, and the data backs up several of their concerns:
  • Losses have expanded over the past five years at about 7.6% annually, and the company is not forecast to reach profitability over the next three years despite revenue growth forecasts of about 21.5% a year.
  • Quarterly net losses in FY 2025 ranged from US$15.8 million to US$23.8 million, which supports the bearish view that high cash burn and operating losses could keep pressure on future funding needs.

A cautious investor looking at these loss levels might want to understand how skeptics think the story could play out over time, and what would need to change to shift that view. 🐻 Personalis Bear Case

Revenue Momentum Versus Deep EPS Losses

• Across FY 2025, quarterly revenue moved between US$14.5 million and US$20.6 million, while basic EPS losses ranged from US$0.18 to US$0.26 per quarter, showing that keeping revenue in the mid tens of millions has not yet translated into positive earnings.
• The bullish narrative leans heavily on revenue growth and product adoption, and there are points where the current numbers support and challenge that stance:
  • Forecast revenue growth of about 21.5% per year and trailing twelve month revenue of roughly US$69.6 million line up with the bullish idea of a growing top line, especially as bulls expect even higher annual growth in some scenarios.
  • At the same time, trailing EPS at a loss of US$0.91 and annual net losses above US$80 million mean that, even under bullish assumptions, the path to earnings targets relies on a major shift from the current loss profile.

Bulls see current revenue traction as a foundation for future earnings, so it can be useful to see how that optimistic case is built from these figures and where it might be stretched. 🐂 Personalis Bull Case

High 9x P/S And Analyst Upside

• Personalis trades on a P/S of about 9x, which is well above the US Life Sciences industry average of roughly 3.4x and a peer average of about 3.1x, while analysts collectively see a current share price of US$5.99 against a consensus target of US$11.29.
• Consensus narrative highlights both opportunity and risk in that gap, and the figures give you a clearer sense of the trade off:
  • Analysts project around 21.5% annual revenue growth and an implied upside of about 88.4% from the current share price to the US$11.29 target, which matches the idea that the market could be underestimating future growth.
  • However, the stock already carries a higher P/S multiple than industry and peer averages while the company remains unprofitable, which lines up with concerns that a lot of growth expectation is already embedded in the valuation.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Personalis on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment split between the heavy losses and the growth story, it helps to move quickly from headlines to the underlying data and form your own judgment using the 2 key rewards and 3 important warning signs.

See What Else Is Out There

Personalis combines a high 9x P/S multiple with heavy annual net losses of US$81.3 million and trailing EPS at a loss of US$0.91, which highlights meaningful risk.

If that mix of rich valuation and sizeable losses feels uncomfortable, you can quickly compare it with companies screened for stronger downside protection using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.